Qiagen N.V. (QGEN)
NYSE: QGEN · Real-Time Price · USD
50.33
-0.53 (-1.04%)
At close: Nov 6, 2026, 4:00 PM EST
50.40
+0.07 (0.14%)
After-hours: Nov 6, 2026, 7:30 PM EST
Qiagen Revenue
Qiagen had revenue of $547.87M in the quarter ending September 30, 2026, with 2.87% growth. This brings the company's total for the last twelve months to $2.12B, up 2.17% year-over-year. In the year 2025, Qiagen had annual revenue of $2.09B with 5.65% growth. That makes Qiagen the 4,812th largest company in the world by revenue and 1,265th in the United States.
Revenue (ttm)
$2.12B
Revenue Growth
+2.17%
P/S Ratio
4.91
Revenue / Employee
$391,787
Employees
5,400
Market Cap
10.39B
Revenue by Geography
- United States 998.45M 47.8%
- Europe, Middle East and Africa 712.76M 34.1%
- Asia Pacific, Japan and Rest of World 290.73M 13.9%
- Other Americas 88.07M 4.2%
Fiscal year ended Dec 31, 2025 See the full Qiagen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.09B | 111.79M | 5.65% |
| Dec 31, 2024 | 1.98B | 12.90M | 0.66% |
| Dec 31, 2023 | 1.97B | -176.21M | -8.23% |
| Dec 31, 2022 | 2.14B | -110.14M | -4.89% |
| Dec 31, 2021 | 2.25B | 381.31M | 20.39% |
| Dec 31, 2020 | 1.87B | 343.92M | 22.53% |
| Dec 31, 2019 | 1.53B | 24.58M | 1.64% |
| Dec 31, 2018 | 1.50B | 84.31M | 5.95% |
| Dec 31, 2017 | 1.42B | 79.55M | 5.95% |
| Dec 31, 2016 | 1.34B | 57.01M | 4.45% |
| Dec 31, 2015 | 1.28B | -63.79M | -4.74% |
| Dec 31, 2014 | 1.34B | 42.79M | 3.29% |
| Dec 31, 2013 | 1.30B | 47.53M | 3.79% |
| Dec 31, 2012 | 1.25B | 84.71M | 7.24% |
| Dec 31, 2011 | 1.17B | 82.32M | 7.57% |
| Dec 31, 2010 | 1.09B | 77.61M | 7.69% |
| Dec 31, 2009 | 1.01B | 116.85M | 13.09% |
| Dec 31, 2008 | 892.98M | 243.20M | 37.43% |
| Dec 31, 2007 | 649.77M | 184.00M | 39.50% |
| Dec 31, 2006 | 465.78M | 67.38M | 16.91% |
| Dec 31, 2005 | 398.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.23B |
| Charles River Laboratories International | 3.98B |
| Revvity | 2.94B |
| Medpace Holdings | 2.84B |
| RadNet | 2.27B |
| Guardant Health | 1.28B |
| Sotera Health Company | 1.23B |
| CareDx | 497.40M |
QGEN News
- 1 day ago - Qiagen shareholders approve Jonathan Pratt as managing director - TheFly
- 1 day ago - QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director - Business Wire
- 1 day ago - Qiagen Transcript: EGM 2026 - Transcripts
- 3 days ago - Qiagen reports Q3 EPS 65c, consensus 63c - TheFly
- 3 days ago - QIAGEN Reports Full Q3 2026 Results - Business Wire
- 3 days ago - Qiagen Earnings release: Q3 2026 - Filings
- 10 days ago - BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ultralife Corporation (Nasdaq – ULBI), QIAGEN N.V. (NYSE – QGEN), CCC Intelligent Solutions Holdings Inc. (Nasdaq – CCC), Penske Automotive Group, Inc. (NYSE – PAG) - GlobeNewsWire
- 11 days ago - Qiagen downgraded to Equal Weight from Overweight at Barclays - TheFly